T.Man Pharmaceutical Public Company (TMAN) Fair Value & Analysis
Healthcare · TH · Market cap 4.4B THB
Fair value as of: Jun 24, 2026
Analysis
T.Man Pharmaceutical Public Company (TMAN) currently trades at 10.60 THB, while our model-based Fair Value estimate is 17.80 THB — implying the stock looks roughly 67.9% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties' Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatological, mouth, and throat products. The company also provides herbal and traditional medicines, dietary supplements, vitamins and minerals, skin care and aesthetics, whey protein, and mommy and kid products, as well as cosmetics, modern medicines, mossi guard, nevtral, propolis, and vita-c products. In addition, it offers products under various brand names, such as Iyara, Propoliz, POLAR, and Fibermate. The company also exports its products. Further, the company offers original equipment manufacturing services. Add…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is T.Man Pharmaceutical Public Company (TMAN) undervalued?
What is the fair value of TMAN?
What is the quality score of TMAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.